Alliance Pharma (LON:APH), the company that breathes new life into brands offloaded by the drugs majors, has seen solid growth in 2015.
Trading in the first four months of 2015 was described as "satisfactory" by chairman Andrew Smith in a statement issued ahead of the firm's annual general meeting on Wednesday.
Revenue of £15.6mln was up 6% year-on-year, with eczema cream Hydromol, the group's biggest brand, leading the charge with a 14% increase in sales.
The acquisitive company said sales of eye treatment MacuShield in the three months since it acquired it have been in line with expectations, up 12% year-on-year.
"We have a strong pipeline of potential acquisition opportunities and have more than £20 million of undrawn bank facilities available to us," Smith told investors.
The company continues to look forward to supplies of ImmuCyst resuming in the second half of the year; this had previously generated sales of £4mln a year for the company before supply issues led to its withdrawal from the market in the second half of 2012, and although a rival bladder cancer treatment has since emerged to plug the gap in the market, its reintroduction could boost full-year performance, though Smith cautioned that it is not yet clear how quickly supplies of ImmuCyst can be ramped up.